Pan-TXNRD inhibitors, such as auranofin, and specific TXNRD1 inhibitors have been developed in recent years, demonstrating their capacity to induce oxidative stress, to suppress cancer cell growth, and to kill cancer cells, hence confirming their therapeutic anticancer potential [58,59]. Here, TXNRD1 is linked to cancer.